Short Interest in Seelos Therapeutics, Inc. (NASDAQ:SEEL) Drops By 69.3%

Seelos Therapeutics, Inc. (NASDAQ:SEEL) saw a significant drop in short interest in the month of October. As of October 15th, there was short interest totalling 52,500 shares, a drop of 69.3% from the September 30th total of 170,900 shares. Based on an average daily trading volume, of 558,600 shares, the days-to-cover ratio is currently 0.1 days. Approximately 4.7% of the shares of the company are short sold.

Seelos Therapeutics Trading Up 3.4 %

Shares of SEEL stock traded up $0.04 during trading hours on Friday, hitting $1.22. 14,985 shares of the company’s stock were exchanged, compared to its average volume of 186,307. The firm has a 50 day moving average of $3.38 and a two-hundred day moving average of $14.77. Seelos Therapeutics has a fifty-two week low of $0.82 and a fifty-two week high of $837.12.

Seelos Therapeutics (NASDAQ:SEEL) last announced its earnings results on Wednesday, August 14th. The company reported $1.92 earnings per share for the quarter. The business had revenue of $0.38 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Seelos Therapeutics stock. Gendell Jeffrey L raised its stake in Seelos Therapeutics, Inc. (NASDAQ:SEEL) by 284.3% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 428,966 shares of the company’s stock after buying an additional 317,351 shares during the quarter. Gendell Jeffrey L owned approximately 2.58% of Seelos Therapeutics worth $254,000 at the end of the most recent quarter. Institutional investors own 23.37% of the company’s stock.

Seelos Therapeutics Company Profile

Seelos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD).